The original version of this article unfortunately contained some mistakes. The corrected details are provided below: "some other glucose-lowering drugs (most frequently semaglutide vs sitagliptin or insulin glargine [28-32]) [ Table 3 ]."
Page 817, first column, last para, first sentence, which previously read:
"GLP-1RAs must be administered subcutaneously, which is disadvantage relative to the convenient oral administration of most other classes of glucose-lowering drugs."
Should read:
"GLP-1RAs must be administered subcutaneously, which is a disadvantage relative to the convenient oral administration of most other classes of glucose-lowering drugs."
The original article can be found online at https ://doi.org/10.1007/ s4026 1-019-00826 -0. "glucagon-like peptide-1 receptor analogues"
should read:
"glucagon-like peptide-1 receptor agonists"
The following section was inadvertently omitted:
